🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
48.06
-0.24 (-0.50%)
Nov 20, 2026, 2:08 PM EST - Market open

Travere Therapeutics Stock Forecast

Stock Price Forecast

According to 15 analysts polled by S&P Global, Travere Therapeutics stock has a consensus rating of "Strong Buy" and an average price target of $73.43. The average 1-year stock price forecast is 52.79% higher than the current stock price, while the lowest is $62 (+29.01%) and the highest is $86 (+78.94%).

Price Target: $73.43 (+52.79%)
Analyst Consensus: Strong Buy

Price Target

Chart
TargetLowAverageMedianHigh
Price$62$73.43$73.5$86
Change+29.01%+52.79%+52.93%+78.94%

Analyst Ratings

The average analyst rating for Travere Therapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Chart
RatingJun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Strong Buy121212121212
Buy222222
Hold111111
Sell000000
Strong Sell000000
Total151515151515

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Piper Sandler
Piper Sandler
Buy
Maintains
$68
BuyMaintains$68+41.49%Nov 16, 2026
J.P. Morgan
J.P. Morgan
Buy
Maintains
$90 → $86
BuyMaintains$90 → $86+78.94%Nov 6, 2026
Unknown Analyst
Leerink Partners
No rating
Leerink Partners
Buy
Maintains
$78 → $67
BuyMaintains$78 → $67+39.41%Nov 5, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$89 → $78
BuyReiterates$89 → $78+62.30%Nov 4, 2026
Canaccord Genuity
Canaccord Genuity
Buy
Maintains
$70 → $72
BuyMaintains$70 → $72+49.81%Nov 4, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
765.32M
from 490.73M
Increased by 55.96%
Revenue Next Year
1.14B
from 765.32M
Increased by 48.63%
EPS This Year
0.78
from 0.91
Decreased by -14.19%
EPS Next Year
5.42
from 0.78
Increased by 593.81%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026E
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
131.84M109.46M145.24M233.18M490.73M765.32M
Revenue Growth
-33.52%-16.97%32.69%60.55%110.46%55.96%
Operating Income
-199.43M-319.81M-376.74M-256.18M-62.82M-45.98M
Net Income
-180.09M-278.48M-111.40M-321.55M-25.55M-78.02M
EPS
----0.910.78
EPS Growth
------14.19%
Forward PE
42.8542.8542.8542.8538.0861.55
Free Cash Flow
-----151.00M
No. Analysts
-----14
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High782.2M
Avg765.3M
Low739.7M

Revenue Growth

Revenue Growth202620272028
High
59.4%
Avg
56.0%
Low
50.7%

EPS Forecast

EPS202620272028
High2.51
Avg0.78
Low0.33

EPS Growth

EPS Growth202620272028
High
175.8%
Avg
-14.2%
Low
-63.7%